Graduate School of Medical Sciences
A partnership with the Sloan Kettering Institute

Thomas Norman

Assistant Professor
Norman_Headshot
The Norman Lab aims to combine large-scale functional genomics experiments with computational modeling to enable directed engineering of cell state.

Research

CRISPR genetics and the explosion of experimental methods with single-cell resolution have each transformed our ability to study cell state and how it is perturbed in disease. A second revolution is now unfolding following the marriage of these two fields to produce single-cell CRISPR screens, in which many genetic perturbations (e.g. gene inhibition/activation by CRISPRi/a) are linked in pooled format to high-content measures of their effects (e.g. the transcriptome or morphology). These rich data can both identify genetic perturbations that elicit a particular behavior and catalog the spectrum of phenotypes associated with each genetic perturbation—i.e., one can perform “forward” and “reverse” genetics within the same experiment. The Norman Lab played a foundational role in the development of one of these techniques, Perturb-seq, and continues to develop new approaches to enable massive functional genomics experiments.

Norman_Graphic

Figure 1. Single-cell CRISPR screens enable systematic phenotyping of diverse genetic perturbations. Can we combine these data with models of how phenotypes combine to guide how cell states might be recapitulated or reversed?

A central hypothesis in the lab is that as these single-cell functional genomics approaches scale they will evolve to become tools for directed engineering of cell state. For example, given a cell type and a set of relevant genes, is it possible to predict combinations of those genes whose overexpression will steer the cells towards a desired state? Or can we at least narrow the field so that fewer combinations need to be tested experimentally? This type of directed approach to studying how genes influence cellular phenotype would have many applications. One concrete objective would be to better reconstitute the many in vivo states that ongoing cell atlas projects will reveal, enabling easier and more scalable experiments on in vitro facsimiles. More ambitiously, such experiments could inform efforts to therapeutically normalize the corresponding in vivo cell state. Finally, many fundamental problems in genetics are simply too large to study exhaustively even in the most tractable systems, making a directed approach the only option.

 

The key to making the transition from discovery to engineering of cell states is the addition of a predictive model—some notion of how distinct perturbations interact with each other to yield new phenotypes. We believe techniques like Perturb-seq can provide datasets of the scale, richness, and resolution needed to start building computational models of how phenotypes emerge and that serve as a natural complement to modern machine learning methods that thrive on large interventional datasets.

Current Projects:

  • Single-cell methods development
  • Drivers of fibroblast cell state in disease
  • Modeling of genetic interactions
  • Representation learning for perturbation experiments

Bio

Thomas Norman is an Assistant Member in the Computational & Systems Biology Program at Memorial Sloan Kettering Cancer Center. Born in Canada, he holds bachelor’s and Master’s degrees in engineering and mathematics from Queen’s University in Kingston, Ontario. He completed his Ph.D. in Systems Biology at Harvard University in 2014, working on how stochasticity in gene expression can modify cell fate. His postdoctoral work as a Damon Runyon Fellow in Jonathan Weissman’s lab at UCSF centered on the development of the Perturb-seq approach for conducting CRISPR screens via single-cell RNA sequencing.

Distinctions:

  • Josie Robertson Investigator (2019-2024)
  • Damon Runyon-Dale F. Frey Award for Breakthrough Scientists (2019)
  • Damon Runyon Cancer Research Foundation Fellowship (2015-2018)
  • NIH Director's New Innovator Award (2020)

Selected Publications:

Replogle, J.M.*, Saunders, R.A.*, Pogson, A.N., Hussmann, J.A., Lenail, A., Guna, A., Mascibroda, L., Wagner, E.J., Adelman, K., Bonnar, J.L., Jost, M., Norman, T.M.* and Jonathan S Weissman.* Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. Cell 185, 2559-2575 (2022).

Norman, T.M.*, Horlbeck, M.*, Replogle, J., Ge, A., Xu, A., Jost, M., Gilbert, L., & Weissman, J.S. Exploring genetic interaction manifolds constructed from rich phenotypes. Science 365, 786-793 (2019).

Adamson, B.*, Norman, T.M.*, Jost, M., Cho, M.Y., Nuñez, J.K., Chen, Y., Villalta, J.E., Gilbert, L.A., Horlbeck, M.A., Hein, M.Y. Pak, R.A., Gray, A.N., Gross, C.A., Dixit, A. Parnas, O., Regev, A. & Weissman, J.S. A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response.  Cell 167, 1867-1882 (2016).

Current Areas of Focus

Need more info?
Ask a question
Follow us on
Instagram

Weill Cornell Medicine Graduate School of Medical Sciences 1300 York Ave. Box 65 New York, NY 10065 Phone: (212) 746-6565 Fax: (212) 746-8906